{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-071296","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.123720+00:00","generated_at":"2026-06-21T22:59:05.998056+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Relmada's RELIANCE III MDD trial failed; RELIANCE I results at risk from similar enrollment issues","bullets":["RELIANCE III monotherapy trial failed; placebo group mean change of 23 points at one high-enrolling site; 30% of patients from such sites.","RELIANCE I adjunctive trial results by year-end 2022; 40% of patients from same high-enrolling sites, raising risk of similar failure.","RELIANCE II adjunctive trial results delayed to 2023; protocol changes being implemented.","Q3 2022 net loss $39.4M ($1.31/diluted) vs $42.6M ($2.44) prior year; cash $184.2M.","Company states it has financial flexibility to continue advancing REL-1017."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-071296","json":"https://secwatch.observer/filing/0001213900-22-071296.json","markdown":"https://secwatch.observer/filing/0001213900-22-071296.md","text":"https://secwatch.observer/filing/0001213900-22-071296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022071296/0001213900-22-071296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022071296/ea168442-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:59:05.998056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31d4eba8bb505019557d8019cccf28bc1867857f","claim":"RELMADA THERAPEUTICS, INC. reported the nine months ended September 30, 2022 results: net income $119.1 million, EPS $4.04 per share.","evidence_excerpt":"Net loss for the nine months ended September 30, 2022 and 2021 was $119.1 million and $91.4 million, respectively. The Company had a net loss of $4.04 and $5.36 per share for the nine months ended September 30, 2022 and 2021, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022071296/0001213900-22-071296-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Net income","value":"$119.1 million"},{"label":"EPS","value":"$4.04 per share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"ddff8979bc6c710ac9d89307666a5f730372dab5","claim":"RELMADA THERAPEUTICS, INC. reported the three months ended September 30, 2022 results: net income $39.4 million, EPS $1.31 per diluted share.","evidence_excerpt":"The net loss for the three months ended September 30, 2022, was $39.4 million, or $1.31 per diluted share, compared with a net loss of $42.6 million, or $2.44 per diluted share, for the three months ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022071296/0001213900-22-071296-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Net income","value":"$39.4 million"},{"label":"EPS","value":"$1.31 per diluted share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}